![NCI needs a $250M raise in FY24 to maintain paylines, grant funding levels amid crippling continuing resolutions](https://cdn.cancerletter.com/media/2023/12/01145216/49-44-4x3-1.jpg)
![NCI needs a $250M raise in FY24 to maintain paylines, grant funding levels amid crippling continuing resolutions](https://cdn.cancerletter.com/media/2023/12/01145216/49-44-4x3-1.jpg)
Cover Story
NCI Director's Report
The gridlock in Washington is taking a toll on federally funded cancer research as the partisan wrangling in Congress over border security and funding for Israel and Ukraine shows no sign of relenting.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Funding Opportunities
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
NCI Trials
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
NCI Trials for December 2023
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Robert Gallo named founding director of Microbial Oncology Program at TGH Cancer Institute
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- What are you reading in 2023?
- U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage data
Rankings now include a list of Best Regional Hospitals for Equitable Access - Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence